Distinct biochemical properties of the class I histone deacetylase complexes.

Histone Deacetylase Inhibitors Histone Deacetylases / metabolism Histones / chemistry Multiprotein Complexes Nucleosomes

Journal

Current opinion in chemical biology
ISSN: 1879-0402
Titre abrégé: Curr Opin Chem Biol
Pays: England
ID NLM: 9811312

Informations de publication

Date de publication:
10 2022
Historique:
received: 02 04 2022
revised: 25 05 2022
accepted: 29 05 2022
pubmed: 9 7 2022
medline: 24 9 2022
entrez: 8 7 2022
Statut: ppublish

Résumé

Classical histone deacetylases (HDACs) are enzymes that can hydrolytically cleave acetyl-Lys in histones and other proteins and serve as established drug targets in some forms of cancer. Class I HDACs 1-3 typically exist in a range of multiprotein complexes inside cells and show distinct biological functions in modulating gene expression. In recent years, it has become possible to purify and analyze the structure and enzymatic properties of several of these HDAC complexes, including CoREST, MiDAC, NuRD, Sin3, SMRT, MIER, and RERE. Here, we summarize what is experimentally established and/or computationally predicted about the structure of these complexes to describe their particular catalytic activities and site-specificities with modified nucleosome substrates.

Identifiants

DOI: 10.1016/j.cbpa.2022.102179 PMID: 35803024
pubmed: 35803024
pii: S1367-5931(22)00064-3
doi: 10.1016/j.cbpa.2022.102179
pii:
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
Histones 0
Multiprotein Complexes 0
Nucleosomes 0
Histone Deacetylases EC 3.5.1.98

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102179

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Philip Cole is a founder of Acylin Therapeutics and a consultant for Abbvie regarding p300 acetyltransferase inhibitors. He also is a co-inventor on a U.S. patent application for corin.

Auteurs

Kwangwoon Lee (K)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

Samuel D Whedon (SD)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

Zhipeng A Wang (ZA)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

Philip A Cole (PA)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: pacole@bwh.harvard.edu.

Articles similaires

Structural basis for human OGG1 processing 8-oxodGuo within nucleosome core particles.

Mengtian Ren, Fabian Gut, Yilan Fan et al.
1.00
DNA Glycosylases Nucleosomes Humans 8-Hydroxy-2'-Deoxyguanosine DNA Repair

Clr4

Hyun-Soo Kim, Benjamin Roche, Sonali Bhattacharjee et al.
1.00
Schizosaccharomyces pombe Proteins Schizosaccharomyces Heterochromatin Ubiquitination Cell Cycle Proteins

Heterogeneous enhancer states orchestrate β cell responses to metabolic stress.

Liu Wang, Jie Wu, Madeline Sramek et al.
1.00
Animals Insulin-Secreting Cells Mice Enhancer Elements, Genetic Stress, Physiological

Hyponatremia unleashes neutrophil extracellular traps elevating life-threatening pulmonary embolism risk.

Minoru Inoue, Kazuo Takayama, Rina Hashimoto et al.
1.00
Extracellular Traps Hyponatremia Humans Pulmonary Embolism Reactive Oxygen Species

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de désacétylase d'histone › Distinct biochemical properties of the class I...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › Histone deacetylases › Distinct biochemical properties of the class I...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Histone › Distinct biochemical properties of the class I...
questionsmedicales.fr › Structures macromoléculaires › Complexes multiprotéiques › Distinct biochemical properties of the class I...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Chromatine › Nucléosomes › Distinct biochemical properties of the class I...